Onkologi i Sverige Nr 2

FOR YOUR PATIENTS WITH EARLY-STAGE HR+, HER2- BREAST CANCER

Personalise each chemotherapy decision 1–10

Helena

Uniquely designed to help identify patients who need chemotherapy 1, 3, 11

13

RECURRENCE SCORE® RESULT:

4 %

DISTANT RECURRENCE RISK:

< 1 %

ABSOLUTE CHEMOTHERAPY BENEFIT:*

*Group average This is an example of a node-negative patient

The Oncotype DX ® test goes beyond clinicopathological factors, showing both prognostic and predictive benefits. 1–10

Book a meeting (face-to-face or virtual) to learn more: Contact Neil Yman | nyman@exactsciences.com | +46 735 345199 or Complete the online form at www.oncotypedx.com/contact-nordics or by scanning the QR code

Visit our website oncotypeiq.com/en-gb

Explore case studies of the Oncotype DX ® test

HER2-, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive. References: 1. Paik et al. J Clin Oncol . 2006. 2. Albain et al. Lancet Oncol . 2010. 3. Paik et al. N Engl J Med . 2004. 4. Dowsett et al. J Clin Oncol . 2010. 5. Kalinsky et al. N Engl J Med . 2021. 6. Geyer et al. NPJ Breast Cancer . 2018. 7. Sparano et al. N Engl J Med . 2018. 8. Sparano et al. N Engl J Med . 2019. 9. Sparano et al. Abstract GS1-05, SABCS. 2022. 10. Kalinsky et al. SABCS 2021. GS2 07. 11. Sparano and Paik et al. J Clin Oncol. 2008. Oncotype DX Breast Recurrence Score Oncotype DX, and Recurrence Score are registered trademarks of Genomic Health, Inc.

Exact Sciences is a registered trademark of Exact Sciences Corporation. © 2025 Genomic Health, Inc. All rights reserved. EXS15303_0125_EN_Sweden